Azilect (rasagiline) slows the progression of Parkinson’s disease.

This has been a burning question with MAO-B inhibitors for years...first with selegiline and now with Azilect.

Azilect gives us a glimmer of hope...because a single industry-sponsored study suggests that 1 mg/day might slow disease progression.

But that same study shows that 2 mg/day doesn’t help. This has many experts questioning whether 1 mg/day really works...because it doesn’t make sense that a higher dose wouldn’t work when a lower dose does.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote